Organon & Co | OGN - Assets


Organon & Co reported $13B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Celltrion KRW 768.81B 9.37B Mar/2026
Cspc Pharmaceutical CNY 46.7B 695.56M Dec/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 1.21B 33.61M Jun/2026
Divis Laboratories Ltd INR 200.33B 18.82B Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Kangmei Pharma CNY 13.31B 375.64M Mar/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 63.57M 2.83M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Neuren Pharmaceuticals AUD 342.86M 11.61M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Organigram Holdings CAD 521.31M 9.36M Mar/2026
Organon & Co USD 13B 129M Mar/2026
Ovoca Bio EUR 2.07M 414K Dec/2025
Pharma Mar EUR 393.6M 8.34M Jun/2026
Qiagen NV USD 5.78B 513.9M Mar/2026
Sartorius EUR 9.6B 270.6M Jun/2026
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Tilray USD 2.1B 15.95M Sep/2025
Zealand Pharma A/S 15.3B 647.8M Mar/2026